Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Honghui Zhou

Showing results (21-30 of 143) with videos related to

Pageof 15
Sort By:
Pharmaceutical Statistics|December 31, 2009
Confirmatory analysis for phase III population pharmacokineticsChuanpu Hu, Ji Zhang, Honghui Zhou
Journal of Clinical Pharmacology|February 21, 2018
Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease: An Answer to Optimized Treatment?Hannah Hoseyni, Yan Xu, Honghui Zhou
Journal of Clinical Pharmacology|December 3, 2011
Should clinical pharmacokinetic bridging studies between Caucasian and Asian populations be required for approval of monoclonal antibodies?Honghui Zhou, Yuko Tsukamoto, Hugh M Davis
Pharmacology & Therapeutics|October 25, 2012
Rational development and utilization of antibody-based therapeutic proteins in pediatricsZhenhua Xu, Hugh M Davis, Honghui Zhou
Journal of Clinical Pharmacology|January 30, 2004
"Cocktail" approaches and strategies in drug development: valuable tool or flawed science?Honghui Zhou, Zeen Tong, James F McLeod
Journal of Clinical Pharmacology|February 25, 2015
Clinical impact of concomitant immunomodulators on biologic therapy: Pharmacokinetics, immunogenicity, efficacy and safetyZhenhua Xu, Hugh M Davis, Honghui Zhou
Journal of Pharmacokinetics and Pharmacodynamics|June 22, 2017
Improvement in latent variable indirect response modeling of multiple categorical clinical endpoints: application to modeling of guselkumab treatment effects in psoriatic patientsChuanpu Hu, Bruce Randazzo, Amarnath Sharma, et al.
Journal of Pharmacokinetics and Pharmacodynamics|May 24, 2014
Information contributed by meta-analysis in exposure-response modeling: application to phase 2 dose selection of guselkumab in patients with moderate-to-severe psoriasisChuanpu Hu, Yasmine Wasfi, Yanli Zhuang, et al.
Journal of Pharmacokinetics and Pharmacodynamics|February 18, 2011
Informative dropout modeling of longitudinal ordered categorical data and model validation: application to exposure-response modeling of physician's global assessment score for ustekinumab in patients with psoriasisChuanpu Hu, Philippe O Szapary, Newman Yeilding, et al.
Journal of Pharmacokinetics and Pharmacodynamics|January 1, 2013
Latent variable indirect response modeling of categorical endpoints representing change from baselineChuanpu Hu, Zhenhua Xu, Alan M Mendelsohn, et al.
Pageof 15

Showing results (21-30 of 143) with videos related to

Sort By:
Pageof 15
Pharmaceutical Statistics|December 31, 2009
Confirmatory analysis for phase III population pharmacokineticsChuanpu Hu, Ji Zhang, Honghui Zhou
Journal of Clinical Pharmacology|February 21, 2018
Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease: An Answer to Optimized Treatment?Hannah Hoseyni, Yan Xu, Honghui Zhou
Journal of Clinical Pharmacology|December 3, 2011
Should clinical pharmacokinetic bridging studies between Caucasian and Asian populations be required for approval of monoclonal antibodies?Honghui Zhou, Yuko Tsukamoto, Hugh M Davis
Pharmacology & Therapeutics|October 25, 2012
Rational development and utilization of antibody-based therapeutic proteins in pediatricsZhenhua Xu, Hugh M Davis, Honghui Zhou
Journal of Clinical Pharmacology|January 30, 2004
"Cocktail" approaches and strategies in drug development: valuable tool or flawed science?Honghui Zhou, Zeen Tong, James F McLeod
Journal of Clinical Pharmacology|February 25, 2015
Clinical impact of concomitant immunomodulators on biologic therapy: Pharmacokinetics, immunogenicity, efficacy and safetyZhenhua Xu, Hugh M Davis, Honghui Zhou
Journal of Pharmacokinetics and Pharmacodynamics|June 22, 2017
Improvement in latent variable indirect response modeling of multiple categorical clinical endpoints: application to modeling of guselkumab treatment effects in psoriatic patientsChuanpu Hu, Bruce Randazzo, Amarnath Sharma, et al.
Journal of Pharmacokinetics and Pharmacodynamics|May 24, 2014
Information contributed by meta-analysis in exposure-response modeling: application to phase 2 dose selection of guselkumab in patients with moderate-to-severe psoriasisChuanpu Hu, Yasmine Wasfi, Yanli Zhuang, et al.
Journal of Pharmacokinetics and Pharmacodynamics|February 18, 2011
Informative dropout modeling of longitudinal ordered categorical data and model validation: application to exposure-response modeling of physician's global assessment score for ustekinumab in patients with psoriasisChuanpu Hu, Philippe O Szapary, Newman Yeilding, et al.
Journal of Pharmacokinetics and Pharmacodynamics|January 1, 2013
Latent variable indirect response modeling of categorical endpoints representing change from baselineChuanpu Hu, Zhenhua Xu, Alan M Mendelsohn, et al.
Pageof 15